Research Library

The top resource for free research, white papers, reports, case studies, magazines, and eBooks.

Share Your Content with Us
on TradePub.com for readers like you. LEARN MORE
Understanding and Clarifying the Complexities of HRD Measurements in Cancer
Request Your Free Webinar Now:

"Understanding and Clarifying the Complexities of HRD Measurements in Cancer"

Homologous recombination DNA repair deficiency (HRD) creates a permanent genomic scar in cancer cells for many tumor types.

Furthermore, HRD is a response biomarker for poly (ADP-ribose) polymerase inhibitors (PARPi) effective therapy. Consequently, HRD measurement has the potential to improve cancer therapy as evidenced by over 100 clinical trials that include HRD today. However, measuring and standardizing HRD quantitation is not straightforward. HRD measurements may include germline and somatic mutation testing, a measure of hypermethylation, and metrics of genomic instability including loss of heterozygosity, telomeric-allelic imbalance, and large-scale genomic rearrangements. This webinar brings together academic, clinical, IVD, and pharmaceutical experts in the clinical genomics and therapeutics fields to discuss the promises and challenges of HRD measurement for disease management. 

Our panelists on this session will be Ravindra Kolhe, M.D., Ph.D., FCAP, Vice-Chairman of Pathology, Associate Dean for Translational Research Medical College of Georgia at Augusta University and Associate Director for Genomics at Georgia Cancer Center, John Jiang, Ph.D., Senior Director of Medical Affairsat Illumina, David Fabrizio Ph.D., Vice President, Translational Strategy at Foundation Medicine, and Yves Konigshofer Ph.D., Director, Technology Development at LGC Clinical Diagnostics.


Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences

Recommended for Professionals Like You: